Novo Nordisk’s Obesity Care business, which entails the company’s weight loss treatments, has experienced a year-on-year growth spurt. With a 99% sales uptick, the business weighs in at twice as much compared to last year.
Nevertheless, this result did not match what analysts had anticipated before the Danish pharmaceutical giant published its Q2 report on Wednesday. During the months of April, May, and June, sales of the company’s newest obesity drug, Wegovy (semaglutide), came in under what Novo Nordisk had estimated based on analyst projections, booking DKK 1.2bn (USD 164.2m) compared to DKK 1.4bn (USD 191.6m).
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
ALK to exit Turkish market: "It's bad business if all we get is peanuts"
A number of conditions made it unfeasible for the Danish allergy firm to do business in Türkiye, says CEO Carsten Hellmann. Under a calculated and ruthless strategy to focus on markets with momentum, efforts in Italy and Spain have also been reduced.
Genmab postpones crucial cancer candidate decision following Abbvie exit
For the rest of 2022, the Danish biotech firm will share all expenses relating to the development of Duohexabody-CD37 with Abbvie, despite the US-based firm’s decision to withdraw from the collaboration in question.
Genmab says new arbitration builds on a straightforward question
”I think this is a much simpler case than the first arbitration,” says Genmab CEO Jan van de Winkel on the new legal suit brought against Janssen, which stems from a fight Genmab has already lost once.
Top news from MedWatch this week
Miss anything?
Analyst: Upgraded ALK sales guidance could still be beaten
Despite an upgrade, ALK may still beat its own sales guidance, one Sydbank analyst predicts.
Director Regulatory Affairs 
Snr. Talent Acquisition Partner, Devoteam 
Senior CMC Regulatory Manage 
Scientist Radiochemistry 
Principal Laboratory Technologist Medicinal Chemistry 
Quality coordinator for Aseptic Production, ALK 
Sales Director, Nordic Hospital Solutions, at Mediq Denmark 
GMP Compliance Consultant for Eltronic in Ballerup 
Lead Auditor – Senior Quality Assurance Specialist 
Clinical Biometrics Oversight Lead 
Clinical Project Leader/ Sr. Clinical Trial Manager – make a difference and join our mission to bring our IL-22 lead program to patients